{
  "parties": [
    "XENCOR, INC",
    "AIMMUNE THERAPEUTICS"
  ],
  "effective_date": null,
  "governing_law": null,
  "payment_terms": null,
  "termination_clause": {
    "text": "Termination 40\n\nARTICLE 14 Effects of Expiration Or Termination 40\n\nARTICLE 15 Miscellaneous 43\n\nSchedule 1.10 Antibody 50\n\nSchedule 1.79 Xencor General Patents 51\n\nSchedule 1.81 Xencor Product Specific Patents 52\n\nSchedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data 53\n\nSchedule 6.1 Initial Product Supply 54\n\nSchedule 10.2.6 Exceptions 55\n\nSchedule 12.2 Initial Press Release 56\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n\n\n\n\nLICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT\n\nThis License, Development and Commercialization Agreement (this \"Agreement\"), dated as of February 4, 2020 (the \"Effective Date\"), is made by and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune\"). Xencor and Aimmune are sometimes referred to herein individually as a \"Party\"",
    "start": 894,
    "end": 1705,
    "confidence": 0.72,
    "source": "regex"
  },
  "_doc_id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement.txt",
  "_char_count": 167973,
  "_provenance": {}
}